Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
$962M |
| 2 |
Cisco
CSCO
|
$202M |
| 3 |
Amazon
AMZN
|
$165M |
| 4 |
Johnson & Johnson
JNJ
|
$153M |
| 5 |
Pinduoduo
PDD
|
$131M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
$468M |
| 2 |
Merck
MRK
|
$306M |
| 3 |
ATVI
Activision Blizzard Inc.
ATVI
|
$305M |
| 4 |
TWNK
Hostess Brands, Inc. Class A Common Stock
TWNK
|
$299M |
| 5 |
TRTN
Triton International Limited
TRTN
|
$282M |
Sector Composition
| 1 | Technology | 18.21% |
| 2 | Financials | 17.12% |
| 3 | Industrials | 13% |
| 4 | Consumer Discretionary | 11.26% |
| 5 | Healthcare | 10.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3126
Black Diamond Therapeutics
BDTX
$167M
| $312K | ﹤0.01% |
110,612
+58,354
| +112% | +$165K |
|
3127
Nektar Therapeutics
NKTR
$764M
| $309K | ﹤0.01% |
36,444
-2,755
| -7% | -$23.3K |
|
3128
Solid Biosciences
SLDB
$428M
| $307K | ﹤0.01% |
49,950
-5,140
| -9% | -$31.6K |
|
3129
HireQuest
HQI
$142M
| $307K | ﹤0.01% |
19,977
| – | – |
|
3130
Relmada Therapeutics
RLMD
$54.8M
| $305K | ﹤0.01% |
73,820
| – | – |
|
3131
Praxis Precision Medicines
PRAX
$986M
| $305K | ﹤0.01% |
13,710
+12,302
| +874% | +$274K |
|
|
OGI
3132
Organigram Holdings
OGI
$221M
| $304K | ﹤0.01% |
232,330
+13,203
| +6% | +$17.3K |
|
3133
Traeger
COOK
$200M
| $304K | ﹤0.01% |
111,261
+12,777
| +13% | +$34.9K |
|
|
LENZ
3134
LENZ Therapeutics
LENZ
$1.2B
| $303K | ﹤0.01% |
16,499
+1,918
| +13% | +$35.2K |
|
3135
Natural Health Trends
NHTC
$52.6M
| $300K | ﹤0.01% |
51,377
+1,823
| +4% | +$10.6K |
|
3136
AC Immune
ACIU
$229M
| $299K | ﹤0.01% |
59,752
| – | – |
|
3137
Gray Media, Inc. Class A
GTN.A
| $295K | ﹤0.01% |
34,467
| – | – |
|
|
GRTS
3138
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $291K | ﹤0.01% |
142,730
-10,370
| -7% | -$21.2K |
|
3139
ImmuCell
ICCC
$57.3M
| $290K | ﹤0.01% |
57,451
-143
| -0.2% | -$722 |
|
3140
XBiotech
XBIT
$89M
| $290K | ﹤0.01% |
72,475
| – | – |
|
3141
Adicet Bio
ACET
$60M
| $290K | ﹤0.01% |
153,414
-7,491
| -5% | -$14.1K |
|
3142
Zevra Therapeutics
ZVRA
$502M
| $286K | ﹤0.01% |
43,605
-10,285
| -19% | -$67.4K |
|
3143
SWK Holdings
SWKH
$178M
| $284K | ﹤0.01% |
20,466
| – | – |
|
3144
Atea Pharmaceuticals
AVIR
$267M
| $282K | ﹤0.01% |
92,351
| – | – |
|
3145
Absci
ABSI
$368M
| $279K | ﹤0.01% |
66,533
+36,218
| +119% | +$152K |
|
3146
Air T
AIRT
$68.9M
| $273K | ﹤0.01% |
16,569
-54
| -0.3% | -$891 |
|
3147
First Guaranty Bancshares
FGBI
$130M
| $272K | ﹤0.01% |
24,492
| – | – |
|
|
INZY
3148
DELISTED
Inozyme Pharma
INZY
| $272K | ﹤0.01% |
63,685
+4,244
| +7% | +$18.1K |
|
3149
CVD Equipment Corp
CVV
$19.1M
| $272K | ﹤0.01% |
61,294
| – | – |
|
3150
ThredUp
TDUP
$1.43B
| $271K | ﹤0.01% |
120,233
+81,368
| +209% | +$183K |
|